Clinical Relevance of Reductive Hepatectomy for Barcelona Clinic Liver Cancer Stages B and C Advanced Hepatocellular Carcinoma: A Single-Center Experience of 102 Patients.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
22
6
2019
medline:
29
1
2020
entrez:
22
6
2019
Statut:
ppublish
Résumé
This study aimed to evaluate the clinical relevance of hepatectomy for Barcelona Clinic Liver Cancer (BCLC) stages B and C advanced hepatocellular carcinoma (HCC). A total of 314 patients (149 and 165 BCLC stages B and C, respectively) who underwent hepatectomy were included. Complete hepatectomy (without residual tumors after hepatectomy) and reductive hepatectomy (apparent residual tumors after hepatectomy) were performed for 212 and 102 patients, respectively. Short-term operative and postoperative outcomes, as well as long-term outcomes, were evaluated. The median survival times of patients with stage B disease undergoing complete hepatectomy and reductive hepatectomy were 48.9 and 20.1 months, respectively (p = 0.0075), whereas those of patients with stage C disease were 19.5 and 17.6 months, respectively (p = 0.0140). The 3-year overall survival rates of patients with stage B disease undergoing reductive hepatectomy with and without subsequent local treatments after surgery were 47.5% and 0%, respectively, whereas those of patients with stage C diseases were 18.6% and 0%, respectively. Survival benefits are obvious for both BCLC stages B and C HCC when complete hepatectomy can be performed safely. Reductive hepatectomy is also acceptable for BCLC stages B and C when subsequent local treatment for remnant liver tumors can be performed safely after reductive hepatectomy. Without subsequent local treatment, reductive hepatectomy has little clinical relevance. Thus, a cautious approach to patient selection is required for this aggressive strategy.
Sections du résumé
BACKGROUND
This study aimed to evaluate the clinical relevance of hepatectomy for Barcelona Clinic Liver Cancer (BCLC) stages B and C advanced hepatocellular carcinoma (HCC).
METHODS
A total of 314 patients (149 and 165 BCLC stages B and C, respectively) who underwent hepatectomy were included. Complete hepatectomy (without residual tumors after hepatectomy) and reductive hepatectomy (apparent residual tumors after hepatectomy) were performed for 212 and 102 patients, respectively. Short-term operative and postoperative outcomes, as well as long-term outcomes, were evaluated.
RESULTS
The median survival times of patients with stage B disease undergoing complete hepatectomy and reductive hepatectomy were 48.9 and 20.1 months, respectively (p = 0.0075), whereas those of patients with stage C disease were 19.5 and 17.6 months, respectively (p = 0.0140). The 3-year overall survival rates of patients with stage B disease undergoing reductive hepatectomy with and without subsequent local treatments after surgery were 47.5% and 0%, respectively, whereas those of patients with stage C diseases were 18.6% and 0%, respectively.
CONCLUSIONS
Survival benefits are obvious for both BCLC stages B and C HCC when complete hepatectomy can be performed safely. Reductive hepatectomy is also acceptable for BCLC stages B and C when subsequent local treatment for remnant liver tumors can be performed safely after reductive hepatectomy. Without subsequent local treatment, reductive hepatectomy has little clinical relevance. Thus, a cautious approach to patient selection is required for this aggressive strategy.
Identifiants
pubmed: 31222640
doi: 10.1007/s00268-019-05052-5
pii: 10.1007/s00268-019-05052-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2571-2578Références
J Gastroenterol. 2003;38(3):207-15
pubmed: 12673442
Surg Today. 1993;23(8):675-81
pubmed: 8400670
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Hepatology. 2003 Feb;37(2):429-42
pubmed: 12540794
World J Surg. 2006 Mar;30(3):431-8
pubmed: 16479350
World J Surg. 2010 Sep;34(9):2155-61
pubmed: 20407768
J Gastroenterol. 2012 Oct;47(10):1125-33
pubmed: 22426637
J Hepatol. 2017 Jul;67(1):92-99
pubmed: 28257902
J Hepatol. 2008;48 Suppl 1:S20-37
pubmed: 18304676
Surgery. 2016 Nov;160(5):1227-1235
pubmed: 27395761
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Cancer. 1985 Aug 15;56(4):918-28
pubmed: 2990661
Strahlenther Onkol. 2019 Mar;195(3):254-264
pubmed: 30413833
PLoS One. 2015 Apr 29;10(4):e0124434
pubmed: 25923439
Ann Surg. 2013 May;257(5):929-37
pubmed: 23426336
Ann Surg. 2004 Jan;239(1):53-60
pubmed: 14685100
J Surg Oncol. 2003 Feb;82(2):98-103
pubmed: 12561065
Dig Liver Dis. 2013 Jun;45(6):510-5
pubmed: 23218990
Arch Surg. 1997 Feb;132(2):120-3
pubmed: 9041912
Ann Surg. 2014 Aug;260(2):329-40
pubmed: 24096763
Eur J Surg Oncol. 2015 Sep;41(9):1153-61
pubmed: 26118317
Tumour Biol. 2014 Sep;35(9):8355-8
pubmed: 25195949
J Surg Oncol. 2017 Jun;115(7):791-804
pubmed: 28205284
J Hepatobiliary Pancreat Sci. 2017 Apr;24(4):199-205
pubmed: 28160422
Clin Mol Hepatol. 2016 Jun;22(2):250-8
pubmed: 27377909
Ann Surg Oncol. 2014 Mar;21(3):971-8
pubmed: 24201744
Hepatology. 1998 Sep;28(3):751-5
pubmed: 9731568
J Cancer Res Clin Oncol. 2004 Jun;130(6):362-6
pubmed: 15034789
Semin Liver Dis. 2012 Nov;32(4):348-59
pubmed: 23397536